Wolowacz, Sorrel; Roskell, Neil; Kelly, Steven; … - In: PharmacoEconomics 25 (2007) 10, pp. 863-879
<Emphasis Type="Bold">Background: Age-related macular degeneration (AMD) is the primary cause of vision loss in the elderly and results in significant economic and humanistic burden. The selective vascular endothelial growth factor inhibitor, pegaptanib (Macugen®) is indicated for patients with neovascular AMD....</emphasis>